FDA: Guidance on Medicated Feed for Food-Producing Animals
The U.S. Food and Drug Administration (FDA) has released its final Guidance for Industry, establishing clearly defined durations of use for medically important antimicrobial drugs administered via animal feed. This move marks a significant milestone in the global initiative to combat antimicrobial resistance (AMR).
The primary goal of this guidance is to ensure that all antimicrobials critical to human medicine are used in accordance with the principles of judicious use. Historically, many such drugs were approved with "undefined durations of use," meaning their labels lacked specific instructions on the length of administration. The FDA now requires these labels to be revised, ensuring these drugs are used only for the time necessary to treat, control, or prevent specific diseases.
Under this new framework, drug sponsors must update product labeling to include transparent criteria for the initiation and termination of antimicrobial treatment. The key requirements include:
Initial Targeted Duration: Labels must specify an approximate range of days that veterinarians should consider for a given indication, based on standard clinical practice.
Maximum Duration Cap: Labels must define a maximum duration that cannot be exceeded for a single course of therapy. This cap is designed to provide flexibility for complex clinical scenarios while preventing routine, indefinite use.
Evidence-Based Administration: Durations must be defined by clinical evidence of disease within a group (for treatment and control) or by a specific high-risk window (for prevention). Using slaughter withdrawal periods as a proxy for treatment duration is no longer permitted.
Resistance Mitigation: Labels should include guidance encouraging practices that minimize resistance, for example, advising a shift to a different drug class if no clinical improvement is observed within a certain timeframe.
The FDA intends to work collaboratively with drug sponsors to implement these transitions. The agency anticipates that revised labeling for all affected products will be approved within approximately three years of this guidance's publication.
